Announcement

Collapse
No announcement yet.

Ocrelizumab Shows Superiority to or Comparability with Other Treatments

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    Ocrelizumab Shows Superiority to or Comparability with Other Treatments

    Ocrelizumab Shows Superiority to or Comparability with Other Multiple Sclerosis Treatments




    Efficacy of ocrelizumab, a humanized anti-CD20 monoclonal antibody, was found to be superior to or comparable with 14 other disease-modifying therapies (DMTs) currently approved by the European Medicines Agency (EMA) forrelapsing multiple sclerosis (RMS) in 7 network meta analyses (NMAs). Ocrelizumab also demonstrated a similar safety profile to each of the DMTs in the analysis.

    Investigators found that ocrelizumab was more effective in reducing the risk of 12-week CDP compared to 10 other treatments, including placebo, with no evidence to suggest that any other treatment was more effective than Ocrelizumab. Analysis of the second key efficacy outcome showed that ocrelizumab was also found to be more effective in reducing ARR than 12 other treatments. There were no differences in SAEs or discontinuation due to AEs between ocrelizumab and other DMTs studied.


    Ocrelizumab demonstrated a consistently high probability of ranking the most effective or tolerable treatment across all 4 outcomes when probabilities of the 2 key efficacy outcomes were plotted with the 2 key safety outcomes.





    https://www.mdmag.com/medical-news/ocrelizumab-shows-superiority-comparability-multiple-sclerosis-treatments
Working...
X